Owners are increasingly seeking high-quality veterinary care for their pets. Dogs get cancer at roughly the same rate as humans and the disease accounts for almost half of the deaths of pets over 10 years of age[i].
There are over 180 million dogs and cats in the US[ii] and almost 190 million in Europe[iii] and the American Pet Products Association estimates that the US market for veterinary services was worth USD 15.9 billion in 2016.
Oasmia is currently exploring strategic options for its Animal Health portfolio. [If you are interested in finding out more about the applications of our technology in Animal Health, please contact email@example.com].
[ii] National Pet Owners Survey (2017–2018), APPA.
[iii] Facts & Figures (2017), the European Pet Food Industry Federation
90 million dogs
There were approximately 90 million dogs in the US 2017 and in Europe the corresponding number was 87,5 million1
dog insurance is USD 47
In the US, the average monthly cost for a dog insurance is USD 472
estimated at USD 33 billion
The value of US veterinary services market in 2017 was estimated at USD 33 billion3
Paccal Vet is the only formulation of paclitaxel designed for use in companion animals. It is Oasmia’s lead product candidate in veterinary oncology. Paclitaxel is one of the most commonly used cytostatics in human oncology.
Doxophos Vet is the only doxorubicin-based product candidate specifically designed to treat companion animals with lymphoma, a common cancer in dogs and cats. Doxorubicin is a well-known and effective treatment for lymphoma in humans.
|Paccal Vet® (paclitaxel)||Mammary Carcinoma (Canines)||No||USA|
|Doxophos Vet® (doxorubicin)||Lymphoma (Canines)||No||USA|